Sanofi (SNY) Shares are Up 0.76%

Sanofi (SNY) has been under a strong bear grip, hence the stock is down -1.31% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.82% in the past 1 week. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.76% in the last 1 week, and is up 2.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.01% and the 50-Day Moving Average is 4.6%. Sanofi is up 8.09% in the last 3-month period. Year-to-Date the stock performance stands at 4.16%.


Sanofi (NYSE:SNY): stock turned positive on Friday. Though the stock opened at $41.64, the bulls momentum made the stock top out at $42.74 level for the day. The stock recorded a low of $41.62 and closed the trading day at $42.63, in the green by 0.07%. The total traded volume for the day was 2,060,444. The stock had closed at $42.6 in the previous days trading.

Also, Equity Analysts at the Barclays upgrades the rating on Sanofi (NYSE:SNY). The brokerage firm has issued a Overweight rating on the shares. The shares were previously rated Equal-weight. The rating by the firm was issued on May 12, 2016.

Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The Company is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. The Company invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products. The emerging markets platform includes products from all three of the Companys principal activities. Under the Companys Pharmaceuticals business, products are grouped into the key fields of diabetes solutions, rare diseases, multiple sclerosis, oncology, thrombosis and cardiovascular disease prevention, nephrology and bio-surgery. The Human Vaccines activity is operated through Sanofi Pasteur. The Animal Health activity is carried out through Merial.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.